Johnson & Johnson has been dealing for years with thousands of lawsuits related to its talc-based products, which plaintiffs claim gave them cancer. This issue has somewhat affected the drugmaker's ...
Over the past year, J&J stock barely moved on the days the market rose and gained on the days it fell. During an average up ...
Johnson & Johnson (NYSE: JNJ) reported new oncology data, including a 75% tumor response rate for JNJ-6143 in advanced ...
Johnson & Johnson (NYSE:JNJ) reported 48-week results from its Phase 3 FUZION study evaluating Tremfya (guselkumab) in adults with Crohn’s disease and active perianal fistulas, showing that fistula ...
Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, ...
Monday - Friday, 6:00 - 7:00 PM ET CNBC's Jim Cramer on Thursday told investors why he thinks the stock of Johnson & Johnson is performing well this year even as the broader healthcare sector lags.
Johnson & Johnson will spend $2 billion over the next 10 years renting a 160,000-square-foot facility at Fujifilm Diosynth's massive manufacturing complex in Holly Springs, N.C. ((Photo by Cristina ...
Monday - Friday, 6:00 - 7:00 PM ET As Wall Street navigates a jam-packed start to earnings season, CNBC's Jim Cramer explained what made shares of Johnson & Johnson rise after the company posted its ...
Add Yahoo as a preferred source to see more of our stories on Google. On Sept. 29, 1982, Mary Kellerman woke up feeling sick. The 12-year-old girl from Elk Grove Village, a suburb of Chicago, asked ...
Today, Johnson & Johnson released its financial results for Q3 2025, which once again stunned Wall Street. So, sales of Rybrevant/Lazcluze, the 'diamond' in its oncology franchise, reached $198 ...
Oct 24 (Reuters) - Johnson & Johnson on Saturday said its experimental once-daily oral prostate cancer drug caused tumors to disappear or shrink in an early-stage trial. J&J had gained access to the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results